Posted by Michael Wonder on 10 Nov 2022
Aleta Biotherapeutics receives Innovation Passport Designation for biologic CAR T-cell therapy engager ALETA-001
7 November 2022 - ALETA-001 was developed to address the urgent unmet need of patient relapse after CD19 targeted CAR T-cell cancer treatment.
Aleta Biotherapeutics announces that the UK MHRA has granted an Innovation Passport under the Innovative Licensing and Access Pathway for chimeric antigen receptor T-cell therapy Engager candidate ALETA-001 for the treatment of patients suffering from the B-cell malignancies, non-Hodgkin lymphoma and acute lymphoblastic leukaemia, and who have failed to respond or have relapsed post-CD19 CAR T-cell therapy.
